Albumin Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 7.83 Billion |
| Market Size (2030) | USD 11.38 Billion |
| Growth Rate (2025 - 2030) | 7.76% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Albumin Market Analysis by Mordor Intelligence
The Albumin Market size is estimated at USD 7.83 billion in 2025, and is expected to reach USD 11.38 billion by 2030, at a CAGR of 7.76% during the forecast period (2025-2030).
The outbreak of COVID-19 had a significant impact on the market since albumin infusion was widely used for COVID-19-infected patients. Also, albumin was reported as an important marker for predicting COVID-19. For instance, according to the article published in October 2022 in PubMed, albumin administration was found to regulate COVID-19-related biomarkers and reduce the risk of death in critical patients with hypoalbuminemia. Thus, the pandemic significantly impacted the studied market due to the increase in the adoption of albumin treatments for COVID-19-infected patients. However, in the post-pandemic scenario, with the declining COVID-19 cases, the studied market is anticipated to grow considerably due to the rise in research and development activities using albumin and the improvements in therapeutics for various diseases.
The major factors attributed to the growth of the albumin market include the rise in non-therapeutic applications of albumin and the high demand for albumin in R&D activities. For instance, as per an article published in April 2023 in Frontiers Journal, albumin-based hydrogels demonstrated significant progress in antitumor-drug delivery and tissue regeneration engineering. Due to the controlled mechanical properties, better biocompatibility and better degradability, albumin-based products are utilised by researchers for studies. Moreover, the launch of new products and strategic partnerships by the key players in the market is expected to address the growing need for albumin in addressing many chronic conditions, thereby driving the market. For instance, in January 2022, Bio Products Laboratory (BPL), a manufacturer of plasma-derived protein therapies, received National Medical Products Administration (NMPA) license to market ALBUMINEX 25% product to China. ALBUMINEX treats hypovolemia (a condition that occurs when the body loses fluid, like blood or water), ascites, hypoalbuminemia and burns. As albumin effectively reverses hypovolemia, such strategic product launches are likely to increase the demand for albumin products, thereby contributing to market growth over the forecast period.
Furthermore, rising research and development activities and clinical studies demonstrating the advantages of albumin are also expected to boost the market. For instance, in February 2023, Ruijin Hospital sponsored a clinical trial to compare the effects of different amounts of human albumin infusion per week in patients with hospitalised decompensated cirrhosis on 28-day transplant-free survival and to compare further the alleviation of inflammation, reduction of incidence of nosocomial infection, spontaneous bacterial peritonitis (SBP), acute kidney injury (AKI), acute-on-chronic liver failure (ACLF), and 90-day transplant-free survival.
Hence, owing to the increase in clinical studies and the rise in strategic activities by the key payers, the studied market is expected to grow significantly. However, irrational uses and adverse reactions associated with albumin and the rising shift toward serum-free solutions are expected to hinder market growth during the forecast period.
Global Albumin Market Trends and Insights
The Human Serum Albumin Segment is Expected to Witness a Notable Growth in the Studied Market Over the Forecast Period
Human serum albumin (HSA) is the serum albumin found in human blood and is the most available protein in human blood plasma. As one of the most abundant proteins in blood plasma, human serum albumin facilitates the transport of hormones, fatty acids and various compounds through the bloodstream. Also, HSA helps in maintaining osmotic blood pressure in the body. Human serum albumin is utilised under multiple clinical conditions, such as restoration of blood volume, emergency treatment of shock, acute management of burns, and other situations associated with hypovolemia, and hence, they are in high demand worldwide.
Factors such as an increase in hypovolemia conditions due to various chronic diseases, a rise in utilisation of human serum albumin in intensive care units, and an increase in HSA product launches by the key players are expected to fuel the segment growth over the forecast period. For instance, cancer patients are likely to be hypovolemic due to continuous vomiting and diarrhoea or inadequate intake of fluids. An increase in cancer cases is expected to raise the demand for HSA, bolstering market growth. For instance, according to the American Cancer Society 2023 Cancer Statistics, about 1.93 million cancer cases are estimated to be reported in 2023 in the United States. The high burden of cancer is expected to augment the demand for HSA, thereby boosting segment growth over the forecast period.
Furthermore, the presence of key players and their strategic activities like product launches, collaborations and agreements are likely to raise the availability and demand for the HSA over the forecast period. For instance, in November 2021, Grifols launched its latest albumin portfolio innovation, ALBUTEIN FlexBag (Albumin [Human] U.S.P.), in 5% and 25% concentrations. Furthermore, an increase in research studies demonstrating the advantages the HSA offers in various therapies will likely contribute to the market growth over the forecast period. For instance, as per the article published in February 2023 in the RSC Advances journal, the researchers demonstrated that compared with individual chemotherapy or photodynamic therapy (PDT) nanoplatforms, hollow human serum albumin had a better anticancer effect via the combination of PDT with chemotherapy after loading photosensitiser Ce6 and anticancer drug DOX. Hence, with such advances and benefits offered by the HSA in chronic disease treatment, the studied segment is expected to grow significantly over the forecast period. Additionally, hypoalbuminemia is considered one of the significant indications of protein-calorie malnutrition and chronic liver disease. Thus, an increase in research funding related to nutrition can include the research and development support of various HSA products, which is expected to augment the segment growth over the study period.
Thus, due to the increase in the adoption of HSA in chronic disease treatment, and the rise in strategic product launches by the key players coupled with benefits offered by the HSA in drug delivery, the studied segment is expected to witness notable market growth over the forecast period.
Geography Analysis
The North American region is expected to witness healthy growth over the forecast period, owing to the presence of key market players and their strategic activities, the rise in cancer cases, which leads to hypoalbuminemia and a surge in research and development activities to develop albumin-based products.
The increase in liver cancer among the North American population is on the rise, which is expected to raise the demand for HSA, as hepatic cell carcinoma patients with lower serum albumin levels had significantly larger maximum tumour diameters compared to higher albumin level patients. For instance, according to the Canadian Cancer Society, 3,500 Canadians were diagnosed with liver cancer in 2022. These cancers mainly affect adults and are more common in men than women. Further, according to a study published in March 2022 in PubMed, hypoalbuminemia was an independent risk factor for tumour progression in early-stage, non-ablative hepatocellular carcinoma (HCC). Thus, the high prevalence of HCC is expected to bolster the demand for albumin-based products, which is further likely to augment the market growth in North America over the forecast period.
Moreover, strategic activities by the key players, such as product launches, partnerships, acquisitions, and rising investments, are further expected to drive the market as these activities are likely to increase the availability of albumin products across the North American region. For instance, in July 2022, EKF Diagnostics revealed the availability of the FDA-cleared Lucica Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corp. and sold exclusively in the United States by EKF. Lucica Glycated Albumin-L is a specific, quantitative glycated albumin test for intermediate-term glycemic control monitoring in patients with diabetes. It is an enzymatic method for compatible clinical chemistry analysers with open channel capability.
Thus, due to the high prevalence of chronic disease, which requires albumin-based treatment and the rise in strategic product launches by the key players, North America is expected to witness significant market growth over the forecast period.
Competitive Landscape
The albumin market is fairly competitive and consists of several key market players. In terms of market share, few of the major players currently dominate the market. With the rising need for better healthcare treatments and the increasing prevalence of diseases, a few other smaller players are expected to enter the market. Some of the key players in the albumin market are Akron Biotech, Baxter International Inc., Bristol-Myers Squibb Company, Biotest AG, and Merck KGaA, among others.
Albumin Industry Leaders
-
Baxter International Inc.
-
Bristol-Myers Squibb Company
-
Merck KGaA
-
Grifols (Biotest AG)
-
Thermo Fisher Scientific
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- March 2023: Albumedix and Heartseed presented Recombumin as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first-in-human trial launched. Recombumin, an animal and human-origin-free recombinant albumin, is an excipient in the final formulation of Heartseed's HS-001 treatment.
- September 2022: the life science group Sartorius, through its French-listed subgroup Sartorius Stedim Biotech acquired Albumedix Ltd, a key player in recombinant albumin-based solutions based in Nottingham, United Kingdom.
Global Albumin Market Report Scope
As per the scope of the report, albumin is a water-soluble globular protein produced in the liver and accounts for 50% of blood plasma proteins. It plays a vital role in regulating blood volume and is a transporter for molecules, such as hormones, bile salts, and ions. It is commonly used as a blood volumiser in rare diseases, burns, shocks, liver conditions, and other blood loss trauma and surgeries. The Albumin Market is Segmented by Type (Human Serum Albumin, Bovine Serum Albumin, and Recombinant Albumin), Application (Drug Delivery, Therapeutics, Culture Media Ingredient, Vaccine Ingredient, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| Human Serum Albumin |
| Bovine Serum Albumin |
| Recombinant Albumin |
| Drug Delivery |
| Therapeutics |
| Culture Media Ingredient |
| Vaccine Ingredient |
| Other Applications |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Type | Human Serum Albumin | |
| Bovine Serum Albumin | ||
| Recombinant Albumin | ||
| By Application | Drug Delivery | |
| Therapeutics | ||
| Culture Media Ingredient | ||
| Vaccine Ingredient | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
What is the global market for albumin?
The Albumin Market size is expected to reach USD 7.83 billion in 2025 and grow at a CAGR of 7.76% to reach USD 11.38 billion by 2030.
What challenges does the albumin industry face?
High production costs, regulatory hurdles, and market competition are the major challenges in market growth.
What are the primary applications of albumin in healthcare?
The primary applications of albumin in healthcare include pharmaceuticals, culture media, diagnostics, and medical coating.
What future opportunities exist in the albumin market?
The future of the albumin sector looks promising with growth driven by increasing therapeutic applications, especially in drug delivery, recombinant albumin production, personalized medicine, and emerging markets.
What is the difference between human serum albumin and recombinant albumin?
The primary difference between human serum albumin (HSA) and recombinant albumin lies in their source, production method, and potential applications.
Page last updated on:
